



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 49/00, A23L 9/686, 1/09, 1/308, 1/164		A2	(11) International Publication Number: WO 97/02050 (43) International Publication Date: 23 January 1997 (23.01.97)
(21) International Application Number: PCT/CA96/00434		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 28 June 1996 (28.06.96)			
(30) Priority Data: 08/497,508 30 June 1995 (30.06.95) US 08/670,709 26 June 1996 (26.06.96) US			
(71) Applicant: VEXCO HEALTHCARE INC. [CA/CA]; Bow Valley Square 1, 630 202 6th Avenue S.W., Calgary, Alberta T2P 2R9 (CA).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(72) Inventors: PALMASON, Carol; 435 49 Avenue S.W., Calgary, Alberta T2S 1G3 (CA). WOLEVER, Thomas, M., S.; 135 Mavety Street, Toronto, Ontario M6P 2L8 (CA).		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(74) Agents: ERRATT, Judy, A. et al.; Gowling, Strathy & Henderson, Suite 2600, 160 Elgin Street, Ottawa, Ontario K1P 1C3 (CA).			

(54) Title: SOLID ORAL DIAGNOSTIC TEST MEAL AND METHODS OF USE THEREOF

(57) Abstract

A solid oral diagnostic test meal is provided that contains a carbohydrate source that provides a medically controlled quantity of available carbohydrate when the meal is ingested by a vertebrate subject. In addition, methods and kits are provided for using the diagnostic test meal to monitor postprandial glucose and insulin levels, to diagnose disorders of carbohydrate metabolism, to manage subjects being treated with antidiabetic agents and to self-diagnose diabetes and self-manage diet and antidiabetic drug dosage.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5

SOLID ORAL DIAGNOSTIC TEST MEAL
AND METHODS OF USE THEREOF

Technical Field

10 The present invention relates generally to products for use in metabolic diagnostic tests. In particular, the invention relates to a solid oral diagnostic test meal useful for assessing the metabolic status of a vertebrate subject and methods 15 of using the same.

Background

20 Disorders of carbohydrate metabolism traditionally include diabetes mellitus and impaired glucose tolerance. More recently, insulin resistance has been recognized as a disorder of carbohydrate metabolism that leads to raised plasma insulin concentrations. Raised plasma insulin has been suggested to contribute to the pathogenesis of 25 diabetes, hypertension, raised serum triglycerides, reduced serum HDL cholesterol and atherosclerosis.

30 Diabetes is a well-recognized cause of significant morbidity and mortality. With a prevalence in North America which will approach 10% in the next decade, non-insulin dependent diabetes ("NIDDM") is a major public health concern.

35 NIDDM is the most common diagnosis of patients entering dialysis programs in the United States, a major cause of vision loss and a major contributing factor in cardiac, peripheral and cerebral vascular diseases. Although there is no direct evidence in NIDDM, the success of the Diabetes

Control and Complications trial in showing that improving glucose control markedly reduced the development of diabetes complications in insulin-dependent diabetic patients, suggests that early 5 diagnosis and treatment of NIDDM to reduce hyperglycemia may reduce complications.

Glucose tolerance in a patient is determined by orally administering a standard amount of glucose and monitoring the responsive blood glucose levels 10 over time. For example, when a normal fasting person ingests 50 grams of glucose, his blood glucose level rises from a fasting level of approximately 90 mg/dL to approximately 140 mg/dL and falls back to the fasting level within about three hours. A diabetic 15 person typically has a fasting blood glucose level above 120 mg/dL. On ingesting 50 grams of glucose, a diabetic exhibits a rise in blood glucose levels for about two to three hours and the blood glucose level falls back to the diabetic fasting level after about 20 five to six hours or more. It has been reported that the postprandial blood glucose response in subjects with normal or abnormal carbohydrate metabolism can be blunted by consumption of a high-carbohydrate, high-fiber bar (McIvor et al. (1985) *Diabetes Care* 8:274- 25 278).

A patient with impaired glucose tolerance ("IGT") displays an abnormal glucose tolerance in which the blood glucose levels are not high enough to be associated with the specific complications of 30 diabetes. However, despite the fact that IGT is a major risk factor for the development of NIDDM, peripheral vascular disease and cardiovascular disease, widespread screening for IGT and asymptomatic NIDDM has not been routinely conducted. Furthermore, 35 screening for hyperinsulinemia and postprandial blood insulin levels is currently only done for research

purposes. Screening may become more common if easier and less expensive methods become available.

The internationally accepted method of diagnosing diabetes, IGT, NIDDM and hyperinsulinemia 5 is to administer a 75-gram oral glucose tolerance test ("OGTT"). The main reason for the use of this test is that a postprandial blood glucose value is needed to make an accurate diagnosis; the use of fasting glucose alone lacks adequate specificity and sensitivity 10 (Modan et al. (1994) *Diabetes Care* 17:436-439).

Glucose is used because it is easy to standardize the amount administered, it is easily stored and its absorption is not influenced by other food factors such as protein or fat, cooking and processing. 15 However, the OGTT has drawbacks and is not commonly done as a clinical test. Thus, diabetes, IGT and hyperinsulinemia are not generally diagnosed early.

One of the drawbacks of the OGTT is the difficulty of the test, which requires a 12- to 16- 20 hour fast and a timed blood sample. In addition, glucose is generally unpalatable and 75 grams is a large dose that may lead to nausea and other gastrointestinal side-effects. Moreover, the results of the test are highly variable often leading to false 25 positives and false negatives.

The diagnosis of diabetes is established if fasting venous plasma glucose at least 140 mg/dL (7.8 mmol/L) or plasma glucose is at least 200 mg/dL (11.1 mmol/L) two hours after the ingestion of an oral 75- 30 gram glucose load (National Diabetes Group (1979) *Diabetes* 28:1039-1057); WHO Expert Committee (1980) *Diabetes Mellitus*, Geneva, World Health Organization (Tech. Rep. Ser. no. 646)), as is customarily performed in an OGTT. These values differ slightly if 35 venous whole blood or capillary whole blood samples are used. In 334 subjects who took repeated 100-gram OGTTs, the median 2-hour postprandial plasma glucose

concentration and within-subject standard deviation ("SD") thereof were 84.0 mg/dL and 12.2 mg/dL, respectively (McDonald et al. (1965) *Diabetes* 14:473-480). The coefficient of variation (SD/mean x 100) of 5 these data was about 14.5%. These data indicate the high variability of the results obtained from an OGTT. Because of this variability it is difficult to interpret the results of an OGTT.

In addition, glucose is a non-physiological 10 test meal and stimulates a relatively weak postprandial insulin response compared to the oral glucose-stimulated postprandial blood glucose response. Although the blood glucose response of starchy foods is less than that of glucose, the 15 insulin response to starchy foods is greater, possibly because of the presence of fat and protein (Bornet et al. (1987) *Am. J. Clin. Nutr.* 45:588-595; Chew et al. (1988) 47:53-56; Indar-Brown et al (1992) *Am. J. Clin. Nutr.* 55:89-95). Accordingly, postprandial insulin 20 responses are not routinely measured and cannot be accurately screened using an oral administration of liquid glucose.

It is clear that near-normal glycemic 25 control can prevent diabetic complications. However, early interest in mass screening for diabetes to facilitate early diagnosis and prevent debilitating or fatal complications was tempered by the undesirable economic, social, physical and psychological consequences of diagnosing diabetes. The current 30 absence of a successfully implemented diabetes mass screening program is the result of the lack of resolution of these concerns (Harris et al. (1994) *Diabetes Care.* 17:440-445; Knowler (1994) *Diabetes Care* 17:445-450).

35 Current interest in diabetes screening programs have fostered studies on, for example, random capillary blood glucose measurements (Engelgau et al.

(1995) *Diabetes Care* 18:463-466) and questionnaires to evaluate the prevalence of diabetes risk factors and thereby prospectively identify subjects at increased risk for undiagnosed diabetes (Herman et al. (1995) 5 *Diabetes Care* 18:382-387). These tests have proven to be variable, empirical and qualitative. Selecting those subjects from the general population who present risk factors merely identifies candidates for more precise and quantitative tests.

10 Accordingly, there is a need in the art for a standardized, physiologically balanced diagnostic test meal that can be used as a diagnostic tool as well as a tool to assist in the management of disorders of carbohydrate metabolism.

15

Summary

20 Central to the present invention is the discovery that the novel solid diagnostic test meal disclosed herein produces a more precise measurement of postprandial glucose and insulin responses compared to liquid glucose beverages and liquid meals.

25 Accordingly, the present invention provides a solid oral diagnostic test meal for use in the diagnosis and management of disorders of carbohydrate metabolism.

30 In one embodiment the invention is directed to a solid oral carbohydrate diagnostic meal comprising a carbohydrate source providing a standardized quantity of available carbohydrate when the meal is ingested by a vertebrate subject.

35 In another embodiment, the invention is directed to a method of determining a postprandial glucose response that involves providing a solid oral carbohydrate diagnostic meal, orally administering the solid oral carbohydrate diagnostic meal to a vertebrate subject and assaying postprandial glucose in a biological sample.

In yet another embodiment, the invention is directed to a method of diagnosing disorders of carbohydrate metabolism that involves providing a solid oral carbohydrate diagnostic meal, orally 5 administering the diagnostic meal to a vertebrate subject, assaying postprandial glucose concentration in a biological sample and comparing the postprandial glucose concentration in the biological sample with a reference glucose concentration.

10 In a further embodiment, the invention is directed to a method of managing the dosage of drugs that are used to decrease postprandial blood glucose. The method involves providing a solid oral carbohydrate diagnostic test meal, orally 15 administering the test meal to a vertebrate subject, assaying postprandial glucose concentration in a biological sample, and repeating the oral administration of the test meal and the assay of glucose concentration in the biological sample after 20 administration of the drug.

25 In still another embodiment, the invention is directed to methods of self-diagnosis and self-monitoring. The methods involve providing a solid oral carbohydrate diagnostic test meal, ingesting the test meal and assaying postprandial glucose concentration in a biological sample.

30 In still other embodiments, kits are provided for diagnosing disorders of carbohydrate metabolism in a vertebrate subject, for managing the dosage of a drug that decreases postprandial glucose concentration in a biological sample from a vertebrate subject, for determining postprandial glucose concentration in a biological sample from a vertebrate subject, for determining a postprandial insulin 35 response in a vertebrate subject and for diabetes self-diagnosis and self-monitoring in a vertebrate subject, wherein the kits comprise a solid oral

diagnostic test meal comprising a carbohydrate source that provides a medically controlled quantity of available carbohydrate when the meal is ingested by the vertebrate subject.

5

Brief Description of the Figures

FIG. 1 is a graphical illustration of the postprandial blood glucose response in subjects after administration of acarbose (open symbols) or a placebo 10 (closed symbols) and consumption of Ensure® as described in Example 6. The data points represent the mean blood glucose level in mmoles/L (mm/L), plus or minus the standard error of the mean, for six determinations at each time point.

15

FIG. 2 is a graphical illustration of the postprandial blood glucose response in subjects after administration of acarbose (open symbols) or a placebo (closed symbols) consumption of a solid test meal as described in Example 6. The data points represent the 20 mean blood glucose level in mmoles/L (mm/L), plus or minus the standard error of the mean, for six determinations at each time point.

25

FIG. 3 is a graphical illustration of the postprandial blood glucose response in subjects after administration of acarbose and consumption of a solid test meal (open symbols) or Ensure® (closed symbols) as described in Example 6. The data points represent the 30 mean blood glucose level in mmoles/L (mm/L), plus or minus the standard error of the mean, for six determinations at each time point.

Detailed Description

The practice of the present invention will employ, unless otherwise indicated, conventional 35 methods of chemistry, biochemistry, medicine, nutritional analysis and food formulation, within the skill of the art. Such techniques are explained fully

in the literature. See, e.g., Bergmeyer et al., eds. *Methods of Enzymatic Analysis*, Academic Press (New York), U.S. Dept. HEW (1982) *Lipid and Lipoprotein Analysis: Manual of Laboratory Operations, Lipid Research Clinics Program*, (Washington, DC), AOAC (1980) *Official Methods of Analysis* (Washington, DC), National Diabetes Group (1979) *Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance*, *Diabetes* 28:1039-1057, Furia (1972 and 1980) *Handbook of Food Additives*, 2d ed., Volumes I and II, CRC Press Inc. (West Palm Beach, FL), and Committee on Specifications, Committee on Food Protection, National Research Council (1980) *Food Chemicals Codex*, 3d ed., National Academy of Sciences (Washington, DC).

All publications, patents and patent applications cited herein, whether *supra* or *infra*, are hereby incorporated by reference in their entirety.

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise. Thus, the term "a blood glucose measurement" can include more than one such measurement.

25

A. Definitions

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below. Although reference is made to blood as a biological sample in the following definitions, the term is intended to encompass other biological samples as well.

By "glycemic response" is meant the amount of glucose produced in the blood following ingestion of a food, test meal or the like taken at a specific postprandial time point, for example, 30, 60, 90 and/or 120 minutes. A subject's glycemic response may

be expressed as a percentage the response to a control standard, for example, a 75-gram glucose-containing beverage, e.g., Glucodex® (Bouvier, Inc., Camble, Quebec). Preferably the glycemic index is taken 60 5 minutes postprandial.

The "glycemic index" of a food, test meal or the like ("GI") is defined as $(F/S) \times 100$ where F is the area under the curve ("AUC") of the glycemic response taken at multiple time points from 0 to 120 10 minutes after ingestion an amount of the food or test meal that provides 50 grams of available carbohydrate and S is the AUC of the glycemic response after ingestion of a reference food that provides 50 grams of available carbohydrate. Preferably the reference 15 food is white bread or a liquid glucose beverage. In determining the glycemic index of a food or test meal, F and S are taken in a subject; preferably S is determined in triplicate and the mean value is used to calculate the GI. The GI of a food or test meal is 20 preferably calculated as the mean of the GIs for that food or test meal that has been determined in about three to ten or more subjects.

The "area under the curve" ("AUC") used to calculate the glycemic index of a food or test meal is 25 the incremental area under the curve of the glycemic response above fasting glucose levels. For example, the AUC can be calculated geometrically as follows, wherein I_n is the difference between the blood glucose level at time n and the fasting blood glucose level 30 and Δt is the time interval between I_n and I_{n-1} . Blood samples are taken after a 10- to 16-hour fast and at n time points from 0 to 120 minutes or more after ingestion of the food or test meal has begun. AUC is the sum of A_n over n time points wherein: $A_n = (\Delta t \times 35 (I_n + I_{n-1}))/2$, when both I_n and I_{n-1} are greater than 0; $A_n = (\Delta t \times (I_n)^2)/(2 \times (I_n - I_{n-1}))$, when I_n is greater than 0 and I_{n-1} is less than 0; $A_n = (\Delta t \times (I_n -$

$I_1)^2) / (2 \times (I_{n-1} - I_n)$, when I_n is less than 0 and I_{n-1} is greater than 0; and $A_n = 0$, when I_n and I_{n-1} are less than 0.

5 The glycemic index expressed as AUC may be used as a basis for dietary carbohydrate exchange and as a reference for assessing the glucose response to a particular food. (see, Jenkins et al. (1981) *Am. J. Clin. Nutr.* 34:362-366, and Jenkins et al. (1983) *Diabetologia* 24:257-264). The glycemic index may be 10 determined as described in Wolever et al. (1985) *Diabetes Care* 8:418-428, Wolever et al. (1991) *Am. J. Clin. Nutr.* 54:846-854 and Wolever et al. (1994) *Am. J. Clin. Nutr.* 59:1265-1269.

15 By "available carbohydrate" is meant the amount of total carbohydrate ingested which can be digested and absorbed. Total carbohydrate is calculated by difference, i.e., total carbohydrate ("TC") is calculated using the equation $TC = S - M - A - F - P$, where S is the weight of the food sample, M is the moisture content, A is the ash content, F is the fat content and P is the protein content. The 20 methods for measuring moisture, ash, fat and protein are described in, e.g., *AOAC Official Methods of Analysis* (1980) Washington, DC, Association of Official Analytical Chemists. Available carbohydrate is the difference between total carbohydrate and dietary fiber in a food sample. Dietary fiber can be measured, e.g., according to the method of Prosky et al. (1988) *J. Assoc. Off. Anal. Chem.* 71:1017.

25 By "management of disorders of carbohydrate metabolism" is intended both the pharmacological diminution of postprandial blood glucose levels and/or insulin responses, a decrease in insulin resistance and a decrease in the medical sequelae which are the hallmark of such diseases, as well as the titration of 35 drug dosage for the treatment of these diseases in individual subjects.

By "medically controlled" is meant that a diagnostic test meal contains a source of carbohydrate that provides a calibrated amount of available carbohydrate which, when administered to a subject, 5 yields a predetermined glycemic response, preferably a predetermined glycemic index. Furthermore, "medically controlled" is intended to mean that the amount of available carbohydrate in a diagnostic test meal is periodically recalibrated to insure the precision of 10 the predetermined response in test subjects and that the glycemic index is monitored to insure precision.

The term "insulin" includes both non-specific insulin and specific insulin. Insulin exists in various forms in the blood, which forms include 15 insulin, proinsulin and a number of split proinsulin products. Non-specific insulin is determined using non-specific antibodies that cross-react with various forms of proinsulin. Specific insulin is determined using antibodies displaying little or no cross-reactivity with proinsulin. Such antibodies can be 20 raised using routine methods well known in the art. Polyclonal serum or monoclonal antibodies can be prepared in response to the desired antigen.

Insulin, proinsulin or split-proinsulin or 25 their fragments can be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal, (e.g., mouse, rabbit, goat, horse, etc.) is immunized with an antigen selected from insulin, proinsulin, split- 30 proinsulin or fragments thereof. Serum from the immunized animal is collected and treated according to known procedures. If serum containing polyclonal antibodies is used, the polyclonal antibodies can be purified by immunoaffinity chromatography, using known 35 procedures.

Monoclonal antibodies to insulin, proinsulin or split-proinsulin, and to fragments thereof, can be

readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by using hybridoma technology is well known. Immortal antibody-producing cell lines can be created by cell 5 fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., Schreier et al. (1980) *Hybridoma Techniques*; Hammerling et al. (1981) *Monoclonal Antibodies and 10 T-cell Hybridomas*; Kennett et al. (1980) *Monoclonal Antibodies*; see also U.S. Patent Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,452,570; 4,466,917; 4,472,500, 4,491,632; and 4,493,890. Panels of 15 monoclonal antibodies produced against the selected antigen can be screened for various properties; i.e., for isotype, epitope, affinity, etc.

A "reference concentration" of glucose or insulin in a biological specimen is that concentration that has been reported as normal for a normal, 20 nonobese, nondiabetic, healthy subject. The reference concentration may be in reference to fasting glucose or insulin or in reference to postprandial glucose or insulin concentration. Such reference concentrations are described in, for example, National Diabetes Group 25 (1979) *Diabetes* 28:1039-1057, and WHO Expert Committee (1980) *Diabetes Mellitus*, Geneva, World Health Organization (Tech. Rep. Ser. no. 646). In addition, a reference concentration may be an intra-subject 30 reference, i.e., a concentration of glucose or insulin in a biological sample previously obtained from the subject being retested.

By "vertebrate subject" is meant any member of the subphylum chordata, including, without limitation, mammals such as cattle, sheep, pigs, 35 goats, horses, and man; domestic animals such as dogs and cats; and birds, including domestic, wild and game birds such as cocks and hens including chickens,

turkeys and other gallinaceous birds. The term does not denote a particular age. Thus, both adult and newborn animals are intended to be covered.

The terms "self-diagnosis", "self-teaching" 5 and "self-monitoring" are meant to encompass the use of the diagnostic test meal in a non-clinic setting. Thus, for example, self-diagnosis is intended to encompass not only the use of the diagnostic test meal by a human subject on himself or herself for the 10 diagnosis of a disorder of carbohydrate metabolism, but also the use of the diagnostic test meal by a party for the diagnosis of a disorder of carbohydrate metabolism in another vertebrate subject.

A "biological sample" may be derived from a 15 variety of sources, e.g., human or other mammalian biological fluids or tissues, including blood (serum or plasma), urine, cerebrospinal fluid, stool, sputum, or wound or glandular exudates, ocular lens fluid, lymph fluid, genital washings, biopsy tissue samples, 20 and the like. One preferred biological sample is blood.

The terms "blood glucose" and "blood 25 insulin" are intended to mean glucose and insulin, respectively, measured in whole blood, serum, or plasma taken from a vein or a capillary bed. Typical sources of capillary blood include finger-, heel, or earlobe-pricks. One of ordinary skill in the art will recognize that the blood glucose level or blood 30 insulin level will vary slightly depending on the source.

The glucose and insulin levels in a biological sample may be measured by any method known in the art. In this regard, glucose levels may be measured using the hexokinase method (Bergmeyer et al. 35 (1974) in Bergmeyer et al., eds. *Methods of Enzymatic Analysis*, Academic Press (New York). Briefly, this assay entails simultaneously incubating the biological

sample with the enzyme hexokinase, which catalyzes the transfer of the γ -phosphate group from adenosine triphosphate ("ATP") to glucose to form glucose-6-phosphate and glucose-6-phosphate dehydrogenase,
5 which, in the presence of nicotinamide-adenine dinucleotide phosphate ("NADP"), catalyzes the conversion glucose-6-phosphate to 6-phosphogluconate and reduced NADP ("NADPH"). The resultant NADPH is coupled to the reduction of iodonitrotetrazolium
10 ("INT"), or other reagent which when chemically reduced forms a colorimetrically detectable species, to form INT-formazan.

Optionally, glucose may be measured, e.g., using glucose oxidase-catalyzed conversion of glucose
15 to gluconic acid, thereby producing hydrogen peroxide, which may be detected colorimetrically by, for example, incubation with 4-aminoantipyrine and *p*-hydroxybenzene sulfonate or *o*-dianisidine in the presence of peroxidase to produce the colorimetrically
20 detectable species quinoneimine dye or oxidized *o*-dianisidine, respectively. By comparison with a standard curve generated using known quantities of glucose, the amount of glucose in the sample can be determined.

25 The individual components required for the above-described glucose assays, as well as kits therefor, may be obtained from any commercial source, e.g., Sigma Chemical Co. (St. Louis, MO).

30 Insulin levels in biological samples may be determined by, for example, radioimmunoassay. Typically, an antibody against insulin is used that cross-reacts with proinsulin and split-proinsulin (Reaven et al. (1993) *J. Clin. Endo. Metab.* 76:44-48). A specific antibody is commercially available which
35 only minimally (< 0.2%) cross-reacts with proinsulin and split-proinsulin (Human Insulin Specific RIA kit, Linco Research, Inc., St. Louis, MO). Assays

employing either antibody may be used to assess the level of insulin in a biological sample. Preferably, a sample may be assayed with the cross-reacting antibody and with the specific antibody in order to 5 determine the amounts of proinsulin present in the biological sample.

The solid oral carbohydrate diagnostic test meal disclosed and claimed herein contains a carbohydrate source providing an amount of starch, 10 i.e., complex carbohydrate, which has been calibrated and standardized to provide a selected quantity of available carbohydrate upon ingestion of the test meal by a vertebrate subject. The preferred source of carbohydrate is oat starch formulated with a 15 standardized quantity of β -glucan from oat grain, other cereal grain including, without limitation, any of the various cultivars of e.g., barley, oat, wheat, rye, corn, maize, sorghum and millet, or another source, such as potato, sweet potato, canna, 20 arrowroot, tapioca (casava) sago, arum, triticale, rice, beans, peas, lentils, chestnuts, peanuts, inulin, lichen, or the like. Alternative, any synthetic starch well known in the art can be included as a carbohydrate source. Other ingredients 25 may also be included such as protein, fat, texture and palatability enhancers and the like. The test meal may be formulated to contain a physiologically balanced carbohydrate source, i.e., the test meal may contain the recommended diabetes dietary requirements 30 of carbohydrate, fat and protein. Such dietary guidelines have been set forth by the American Diabetes Association ("ADA") (1994) *Diabetes Care* 17:519-522, the Canadian Diabetes Association ("CDA") (1989) *Beta Release* 13:8-17, and the European 35 Association for the Study of Diabetes ("EASD") (1988) *Diab. Nutr. Metab.* 1:145-149, the disclosures of which are hereby incorporated in their entirety by

reference. The CDA and EASD recommendations provide that carbohydrate should make up 50% or more of energy intake, fat intake should not exceed 30% of energy intake (of which it is recommended that 10% is 5 saturated fat, 10% is monounsaturated fat and 10% is polyunsaturated fat), protein should be adjusted to meet individual energy requirements, e.g., about 12% to about 15% of energy intake, with the diet having high fiber soluble fiber content, e.g., 40 grams per 10 day or 25 grams per 1000 kilocalories ("kcal"). Current ADA recommendations do not specify total amounts of dietary carbohydrate and fat, but recommend that these dietary components be individualized according to need. The ADA recommendations do provide 15 that less than about 10% of energy intake should be from saturated fat and that about 60% to about 70% of energy intake should be from carbohydrate and monosaturated fat. Energy can be calculated in kcal and converted to kilojoules (kJ) by using the 20 conversion factor of 1 kcal equal 4.18 kJ.

In one preferred formulation, the diagnostic test meal is formulated to contain about 45% to about 75%, preferably 50% to 65%, more preferably 55% to 60% of the energy provided in the meal from carbohydrates, 25 preferably complex carbohydrates. In addition, the test meal may contain about 15% to 30% of energy from fat, low in saturated fat, e.g., less than about 10% to 30% of total fat energy, and higher in monounsaturated fat, e.g., greater than about 25% to 30%, preferably 45% to 55%, of total fat energy, with the remaining fat energy provided by polyunsaturated fat, about 10% to 25% energy from protein, with the optional addition of about 5 to 10 grams of dietary fiber.

35 Among the preferred constituents are fat obtained from vegetable oils, such as canola oil, rapeseed oil, flax oil, borage oil, safflower oil,

soybean oil, coconut oil, evening-primrose oil, castor oil, olive oil, almond oil, peanut oil, linseed oil, corn oil and maize oil, fish oils such as cod liver oil or halibut oil, extracted oat fat or the like, 5 protein obtained from soy flour, egg albumin, ovoglobulin, wheat gluten, whey, lactoglobulin, lactalbumin, meat and blood isolates, serum albumin, fish protein isolates, legume isolates, soy protein, quinoa protein, or the like, and dietary soluble fiber 10 such as β -glucan in oat bran. In order to increase the palatability of the test meal, flavoring such as apple juice, cinnamon, lemon or orange extracts, or the like may be added to the test meal. Other standard food additives may be incorporated into the 15 test meal, for example, acidulants, anticaking agents, antimicrobial agents, antioxidants, baking aids, bleaching agents, buffering agents, bulking agents, carmelization aids, carriers, clarifying agents, clouding agents, colorants, color fixatives, cooking 20 media, defoamers, dough conditioners, emulsifiers, enzymes, filter aids, firming agents, flavor enhancers, flavors, foam stabilizers, food starch modifiers, gums, humectants, hydrocolloids, leavening agents, lubricants, masticatory substances, maturing 25 agents, microorganisms, neutralizers, nonnutritive sweeteners, nutrients and dietary supplements, preservatives, propellants, protein sources, refrigerants, salt substitutes, sequestrants, solvents, stabilizers, surface-active agents, surface- 30 finishing agents, sweeteners, texturizers, thickeners, vitamins, and the like. See, e.g., Furia (1972 and 1980) *Handbook of Food Additives*, 2d ed., Volumes I and II, CRC Press Inc. (West Palm Beach, FL).

In one preferred embodiment, a 90.5-gram 35 solid test meal is provided in the form of a bar. The test meal, having 326 kcal of energy provided by the meal, consists of 50.0 grams of carbohydrate (61.5% of

the meal energy) derived from starch extracted from oat groats, 8.9 grams of fat (24.5% of the meal energy) derived from canola oil and extracted oat fat, 11.4 grams of protein (14.0% of the meal energy) 5 derived from soy flour, egg albumin and/or wheat gluten, 6.9 grams of fiber derived from β -glucan in oat bran, and apple juice, cinnamon and orange juice for flavoring.

A particularly preferred formulation for a 10 133.25-gram (wet weight) test meal in the form of a bar includes the following ingredients (in grams): water (44), rolled oat flakes (19.82), pin-milled flour (available as Ostar® PM flour from Canamino, Inc., Saskatoon, Saskatchewan, Canada) ((13.21), pin- 15 milled starch (available as Ostar® PM starch from Canamino, Inc.) (13.21), oat bran (6.6), liquid honey (9.55), canola oil (7.78), soy protein (5.73), sugar (3.69), glycerin (3.34), gluten (2.86), baking powder (2.192), cinnamon (1.096), salt (0.116), and allspice 20 (0.041).

The amount of available carbohydrate in the test meal may be calibrated to achieve a selected glycemic response or, preferably, a selected glycemic index, determined as described above. A reference 25 glycemic response may be obtained using, for example, an oral liquid glucose standard containing a quantity of glucose, for example, 25 grams, 50 grams, 75 grams or 100 grams of glucose. The amount of available carbohydrate in a test meal may be standardized to 30 achieve a selected 30-minute, 45-minute, 60-minute, 90-minute 120-minute, or the like, postprandial blood glucose response. For a test meal calibrated against an oral liquid glucose reference, it is preferred that the reference glycemic response be determined using a 35 75-gram oral liquid glucose beverage, e.g., Glucodex®. For a test meal calibrated to achieve a selected glycemic index, a preferred reference glycemic index

may obtained using a 50-gram carbohydrate portion of white bread. Thus, for example, the glycemic response or glycemic index obtained for a subject after ingestion of the test meal may be compared to the 5 precalibrated glycemic index or glycemic response of the test meal.

The carbohydrate source can be obtained commercially, e.g., Canamino (Saskatoon, Saskatchewan, Canada). Optionally and preferably, the carbohydrate 10 source may be prepared from cereal grains, and preferably oats, using the method disclosed in U.S. Patent No. 4,435,429, issued to Burrows et al., the disclosure of which is hereby incorporated in its entirety by reference. Briefly, the process involves 15 separation of endospermic tissue from other tissues in grain by first soaking the grain in an aqueous medium, pH 3-7, at 40°C to 70°C until the grain has absorbed at least its own weight of the aqueous medium and the endosperm portion of the grain has been liquified by 20 the action of enzymes indigenous to the cell wall. The grain is then split under pressure to release virtually all the liquified endosperm. The endosperm can then be separated from the other tissues of the grain. The grain can be whole, dehulled or hulless. 25 The aqueous medium preferably contains up to about 0.1 wt.% SO₂. Using this method, low fiber, off-white flour can be produced in the wet or dry state ready for further fractionating.

30 Optionally, and in most cases preferably, the carbohydrate source from cereal grains, preferably oat grains, may be prepared using the method described in U.S. Patent No. 5,169,660, issued to Collins et al., which is hereby incorporated in its entirety by reference. The method involves first steeping the 35 cereal grain in water for a period of time sufficient to substantially completely liquify the endosperm. The steeped grain is then macerated in an aqueous

ethanol solution to liberate the liquid endosperm. Insoluble bran is then separated and recovered from the aqueous ethanol solution and the insoluble flour is separated and recovered from the bran-free aqueous 5 ethanol solution. Recovery of the insoluble bran and flour from the aqueous ethanol solution may be effected by passing the solution over sequentially finer mesh screens. This method is particularly useful for producing relatively pure bran and flour 10 from oat, wheat and rye grains.

The test meal may be in any solid physical form such as a bar, wafer, biscuit, cookie or the like. Preferably, the meal is in the form of a bar. More preferably, the bar is scored to provide two or 15 more portions that may be broken off and ingested if it is desired that the subject ingest a lower quantity, if multiple tests are to be administered or if the subject is a juvenile.

A test meal bar may be made by routine 20 methods well known to those of skill in the art. For example, the components of the test meal may be blended in predetermined proportions with a binding agent, if necessary, selected so as to preserve the component proportions of the bar, e.g., gelatin, β - 25 glucan or wheat gluten, to form a mixture. The mixture may be molded, pressed, poured, extruded or otherwise formed into a desired shape. The shaped bar may also be baked, steamed, dried or otherwise processed, as required, to set the shape of the bar. 30 See, e.g., U.S. Patent No. 5,200,215 to Slade et al.

The test meal disclosed herein produces a more precise ($CV \approx 3\%-5\%$) and more physiological measurement of postprandial glucose and insulin responses compared to liquid glucose beverages such as 35 Glucodex®. Furthermore, the solid test meal produces more precise responses than liquid meals such as Enrich® (Ross Laboratories, Montréal, Canada). Thus,

in using the solid test meal, it is possible to predict blood glucose or insulin responses with only 3%-5% error. Accordingly, the solid test meal can be used as a substitute for the liquid 75-gram liquid 5 glucose standard for the diagnosis and/or management of diabetes mellitus, insulin resistance, impaired glucose tolerance, maturity onset diabetes or gestational diabetes, insulin resistance or for the regulation of hypoglycemia. In addition, the test 10 meal can be used to determine postprandial glucose and/or insulin responses.

Conventional fasting blood glucose or insulin determinations are unreliable for the assessment of disorders of carbohydrate metabolism 15 because as many as 39% of the subjects in the upper range of normal fasted glucose levels show diabetic postprandial glucose responses. Thus, they can only be found with a 60-minute or greater postprandial carbohydrate challenge. Using the novel diagnostic 20 solid test meal disclosed herein, a postprandial glucose response assessment can be initiated one or two hours before clinical laboratory examination, e.g., a subject ingests the test meal one or two hours before blood is drawn at the clinic. In addition, the 25 test meal can be used for self-diagnosis, self-teaching and blood glucose self-monitoring.

Insulin measurements require the ingestion of carbohydrate, fat and protein to be accurate; the OGTT cannot be used to measure postprandial plasma 30 insulin levels accurately. One method for determining postprandial insulin responses using the solid test meal involves first determining a subject's fasting insulin blood levels using methods well known in the art, for example, radioimmunoassay. Postprandial 35 insulin levels are then determined 60, 90 and/or 120 minutes after the ingestion of a diagnostic test meal and compared with predetermined and recognized

standards (see, e.g., Reaven et al. (1993) *Diabetes* 42:1324 and DeFronzo (1988) *Diabetes* 37:667) or compared with previous tests on the individual subject.

5 In addition, the diagnostic test meal can be used in the management of disorders of carbohydrate metabolism. In particular, the test meal can be used as a standard test meal to titrate drug dosage for the treatment of these diseases in individual subjects
10 with oral antidiabetic agents. For example, α -glucosidase inhibitors, e.g., acarbose, are a new class of drugs which improve blood glucose control in diabetics (Clissold et al. (1988) *Drugs* 35:214-243; Chiasson et al. (1994) *Ann. Int. Med.* 121:928-935).
15 Following a liquid test meal, acarbose treatment causes a decrease in the mean glucose peak determined 90 minutes postprandial in patients with NIDDM (Chiasson et al., *supra*). However, flatulence, abdominal distension and diarrhea are major side-
20 effects associated with α -glucosidase inhibitors. This, it is desirable to titrate the dose of acarbose to that dose required to suppress postprandial plasma glucose.

The diagnostic test meal disclosed herein
25 also affords a method by which such dosing regimens can be titrated to an optimal level. In order to assess the dosage of drugs required to decrease postprandial blood glucose a predetermined amount, a solid test meal may be administered to a subject and
30 plasma glucose levels monitored for 0 (i.e., the 10- to 16-hour fasting level) 30, 45, 60, 90 and 120 minutes. The incremental area under the glycemic response curve is calculated geometrically, ignoring area beneath the fasting value (Wolever et al. (1991)
35 *Am. J. Clin. Nutr.* 54:846-854). This procedure is repeated after administration of the antidiabetic agent to determine if the drug produces the desired

diminution in glycemic response. The dose of drug administered is then adjusted upward or downward as necessary to achieve the desired effect. The process may be repeated as often as required until the desired 5 drug response is achieved. In addition, the efficacy of the treatment may be assessed periodically and the drug dosage adjusted as necessary.

A determination of the efficacy of an antidiabetic drug, and whether adjustment of the drug 10 dosage is required, may be made by monitoring changes in the postprandial blood glucose concentration following administration of the drug. Acceptable limits of a drug-induced change in postprandial blood glucose concentration as indicating either acceptable 15 efficacy or a necessity for further titration of the dosage are well known to those of skill in the art. For example, it is generally accepted that, in a subject that has been treated with a first dose of an antidiabetic agent, a second higher or lower dose of 20 the agent that respectively effects a decrease or increase in blood glucose of approximately 2 mmol/L is considered equally efficacious.

An additional use for the solid diagnostic test meal is in the area of self-diagnosis and self-monitoring. Using currently available techniques well 25 known to those in the art, a subject can obtain fasting and postprandial blood samples which can be analyzed for glucose levels using, for example, the One Touch® II blood glucose monitoring system 30 (Lifescan, Inc., Milpitas, California). Optionally, urinary glucose levels may be assessed using the Tes-Tape® glucose enzymatic test strip (Eli Lilly, Indianapolis, Indiana).

Furthermore, as the invention represents a 35 nutritionally balanced meal it can be used in the treatment of hypoglycemia and diabetic shock.

It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, that the description above as well as the examples which follow 5 are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

10

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and 15 use the compounds of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to insure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and 20 deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C and pressure is at or near atmospheric.

B. Experimental

25

Materials and Methods

Finger-prick capillary blood samples ($\approx 200 \mu\text{l}$) were collected into fluoro-oxalate tubes and stored at -20°C for a maximum of 24 hours. Whole blood glucose was measured using a model 2300 STAT 30 glucose analyzer (Yellow Springs Instruments, Ohio). Incremental areas under the glycemic response curves ("AUC") were calculated geometrically, ignoring area beneath the fasting value (Wolever et al. (1991) Am. J. Clin. Nutr. 54:846-854).

35

The mean and standard deviation ("SD") of the results for three repeats of each test meal (unless otherwise indicated) were calculated for each

subject and the coefficient of variation ("CV") was calculated by expressing the SD as a percent of the mean. Where appropriate, analysis of variance was performed with subject and test meal as the variables, 5 and the Neuman-Kuels procedure used to adjust for multiple comparisons.

Plasma insulin was measured by radioimmunoassay. Normally, proinsulin is almost completely cleaved when insulin is secreted. 10 Accordingly, in normal subjects proinsulin is present only in trace amounts in plasma. However, in subjects with IGT and diabetes, insulin secretion is abnormal and larger amounts of proinsulin are present in plasma. Since proinsulin cross-reacts with the 15 antibody in the conventional assay, this may yield results that indicate falsely elevated insulin levels. Although the amount of proinsulin present in plasma of hyperinsulinemic subjects is not enough to account for the hyperinsulinemia, i.e., the true insulin level is 20 elevated (Reaven et al., *supra*), both assays are used for assessing the insulin responses described in the Examples below.

Plasma glucose was measured using the hexokinase method (Bergmeyer et al. (1974) in 25 Bergmeyer et al., eds. *Methods of Enzymatic Analysis*, Academic Press (New York).

All procedures involving human subjects were approved by the University of Toronto Human Subjects Review Committee or other appropriate review 30 committee.

EXAMPLE 1

Determination of Glycemic Index of Test Meal Components

35 The purpose of this experiment was to determine the glycemic index of oat starch, oat flour

and oat bran, which are the main ingredients for the test meal.

Seven normal subjects were studied on six different occasions in the morning after overnight 5 fasts. They ate 50-gram available carbohydrate portions of oat starch (56 gm), oat flour (64 gm), oat bran (105 gm) and white bread (100 gm). The white bread ingestion was repeated three times by each subject for glycemic index calculations. The oat 10 products were prepared by adding 250 ml boiling water to the preweighed product, stirring well and letting stand for three to four minutes. Each test meal was consumed with a 250 ml to 500 ml drink of the subject's choice of water, coffee or tea (with 30 ml 15 2% milk if desired); the drink was standardized for each subject. Finger-prick capillary blood test samples were obtained from the fasting subjects prior to ingestion of the meal and at 15, 30, 45, 60, 90 and 120 minutes after starting to eat the test meal. Test 20 meals were consumed by each subject within 15 minutes. Glycemic index was calculated as the AUC for each oat product expressed as a percent of the mean AUC for the three white bread meals ingested by each subject.

The mean coefficient of variation ("CV") for 25 the seven subjects for fasting blood glucose levels and for blood glucose levels 60 and 120 minutes after white bread ingestion were 2.7%, 3.7% and 5.3%, respectively. The mean CV for the glycemic index was 11.9%. This variability is considerably less than the 30 mean CV of 22% expected based on previous data for normal subjects taking repeated tests of white bread meals.

The glycemic indices (expressed as the mean \pm S.E.M.) of oat starch (124 ± 12) and oat flour (127 ± 19) were virtually identical and not significantly different from that of white bread (100). The peak glycemic responses of oat starch and oat flour were

significantly greater than that of white bread. The glycemic index of oat bran (54 ± 10) was significantly less than that of white bread, as was its peak glycemic response.

5

EXAMPLE 2

Comparison of Reproducibility of the Glycemic Responses

to Oral Glucose Tolerance Tests

and Carbohydrate Diagnostic Test Meals

Ten normal subjects (4 male, 6 female; age: 33 ± 3 years; body mass index ("BMI"): 23.8 ± 1.1 kg/m^2) were studied after 10-12 hour overnight fasts on nine separate mornings over a six-week period. One subject, found to have impaired glucose tolerance during the study, had had a normal OGTT six months prior to the study. Subjects consumed either 75 grams of glucose in 300 ml orange-flavored water (Glucodex®) or a 50-gram carbohydrate portion of white bread or a solid oral carbohydrate diagnostic test meal consisting of an oat bar.

White bread was baked in 250-gram carbohydrate loaves containing 334 grams of all purpose flour (Maple Leaf Mills, Toronto, Ontario), 7 grams of sucrose, 6 grams of yeast, 4 grams of salt and 2500 mL water. Each loaf was cut into 50-gram portions (discarding crust ends).

The oat bar contained bran, starch and flour refined from oats under highly standardized conditions. The 50-gram carbohydrate portion of oat bar weighed 104 grams and contained 352 kcal, 11.7 grams fat, 11.8 grams protein, 42.2 grams starch, 7.8 grams sugars and 5.9 grams dietary fiber. The energy content expressed in kcal can be calculated based on the energy content per gram of fat (9 kcal), protein (4 kcal), available carbohydrate (3.8 kcal), respectively.

The glucose solution was taken with 250 ml water, and bread portions and oat bars were taken with 450 ml water. Subjects repeated each test meal three times and test meals were consumed within 10 minutes.

5 Finger-prick capillary blood samples were collected prior to and 15, 30, 45, 60, 90 and 120 minutes after starting to eat and whole blood glucose was analyzed as described above. Incremental areas under the glycemic response curves were calculated by
10 the method described above.

The mean fasting blood glucose concentration was similar before each of the three test meals. After glucose ingestion, mean blood glucose was significantly greater than after bread and oat bar at
15 every time point; no significant differences were observed in mean blood glucose between bread and oat bar at any time point. The incremental area under the curve after glucose ($284 \pm 42 \text{ mmol} \cdot \text{min/L}$) was greater than after bread ($146 \pm 22 \text{ mmol} \cdot \text{min/L}$) ($p < 0.01$) and
20 oat bar ($124 \pm 19 \text{ mmol} \cdot \text{min/L}$) ($p < 0.01$), with no significant difference between bread and oat bar.

The within-subject CV of blood glucose for the three repeats of oral glucose were greater than for the three bread tests and at 15, 30 and 90 minute
25 (p < 0.05). The CVs for oat bar were not significantly different from glucose or bread, except that at 120 minutes both oat bar and bread CVs were less than after oral glucose (p < 0.01). For seven of the ten subjects, the CV of the 120-minute blood
30 glucose after 75 grams glucose was > 7%, while after bread, seven of the ten subjects had CV < 7%. The mean CV of the areas under the curve was less for bread than oat bar (p < 0.05), but the area CVs for bread and oat bar were not significantly different from that
35 for glucose. The difference between subjects for blood glucose CV was significant at 120 minutes ($F_{(9,18)} = 2.72$) but not at any other time. There was a

positive relationship between the mean 120-minute blood glucose concentration and the CV of the 120-minute blood glucose.

5 The mean within-individual CV of the 2-hour postprandial blood glucose was 12.9% in subjects who had been given 75 grams of glucose. In contrast, the mean within-individual CV of the 2-hour postprandial blood glucose was about 5% for bread or the test meal.

10

EXAMPLE 3

Solid Oral Carbohydrate Diagnostic Test Meal

A typical analysis of a 90.5-gram and a 98.0-gram solid oral carbohydrate test meal is given in Table I below.

15

TABLE I
COMPOSITIONAL ANALYSIS OF A SOLID TEST MEAL

20

25

30

	A	B	Source
Meal Weight	90.5 grams	98.0 grams	
Caloric Content	326 Kcal	350 Kcal	
Fat	8.9 grams (24.5% energy)	11.3 grams	canola oil and extracted oat fat
Protein	11.4 grams (14.0% energy)	12.2 grams	soy flour and/or egg albumin and wheat gluten
Carbohydrate	50.0 grams ^a (61.5% energy)	50 grams (40.5 ^a + 9.5 ^b)	^a oat starch* ^b sugars
Fiber	6.9%	5.9 grams	β -Glucan** in oat bran
Flavoring			apple juice, cinnamon, orange

35

* Starch extracted from oat groats. 80% of the available carbohydrate is from isolated modified oat starch.

** β -Glucan 19% in oat bran.

EXAMPLE 4Evaluation of the Effect of Acarbose on
Glucose Tolerance, Hyperinsulinemia and
Insulin Sensitivity

5 The purpose of this experiment was to evaluate the effect of acarbose, and α -glucosidase inhibitor, on glucose tolerance, hyperinsulinemia and insulin sensitivity in subjects with impaired glucose tolerance. Subjects were randomly treated in a
10 double-blind fashion with placebo (n = 12) or acarbose (n = 11), 100 mg three times a day ("TID") for four months. Each subject was tested as follows before and after treatment.

15 The subjects were fed a liquid test meal followed by measurements of plasma glucose, insulin and proinsulin 30, 60, 90, and 120 minutes postprandial. In addition, an insulin suppression test was done on each subject before and after treatment using the steady state plasma glucose
20 ("SSPG") as an index of insulin sensitivity. Thus, subjects were continuously infused with insulin, somatostatin and glucose for three hours. Plasma glucose levels were taken at 120 minutes, 150 minutes and 180 minutes. The means of these levels (the SSPG)
25 was used as a measure of insulin sensitivity.

30 The mean peak plasma glucose response to the liquid test meal at 60 minutes postprandial was 8.4 ± 0.6 mmol/L before randomization. The respective responses after placebo and acarbose treatment were
35 8.2 ± 0.9 mmol/L and 6.3 ± 0.3 mmol/L ($p < 0.0001$). The mean peak proinsulin response at 120 minutes postprandial was 76.8 pmol/L before randomization. After placebo and acarbose treatment the respective responses were 81.1 pmol/L and 58.2 pmol/L ($p < 0.001$).

 The mean SSPG was 13.3 ± 1.0 mmol/L before randomization. After placebo and acarbose treatments,

the respective mean SPPGs were 13.8 ± 0.4 and 10.0 ± 1.2 mmol/L ($p < 0.032$).

These data indicate that, in subjects with IGT, acarbose treatment induced an improvement in 5 glucose tolerance, a decrease in insulin levels and a decrease in insulin resistance.

EXAMPLE 5

Comparison of the Relationship Between 10 Plasma Glucose and Insulin Responses to Oral Glucose and the Test Meal in Obese Subjects, IGT Subjects and Subjects with Type 2 Diabetes

Four groups of adult (≥ 18 years of age) were studied with 10 volunteers in each group: 15 nonobese ($BMI < 27$ kg/m 2) normal subjects; obese ($BMI \geq 27$ kg/m 2) normal subjects; subjects with impaired glucose tolerance ("IGT") within the last twelve months; and subjects with non-insulin dependent (type 2) diabetes treated by diet alone.

20 Each subject was studied on eight occasions after a 12-hour overnight fast. The subjects consumed either 75 grams of glucose in 300 ml orange-flavored water (Glucodex®) ("GTT") or 50 grams of available carbohydrate in the form of a 98.0-gram test meal in 25 the form of a bar ("TMB") as described in Table I. The test meals were administered to each subject in four consecutive blocks with each block consisting of one GTT and one TMB. The order of tests within each block was randomized, with randomization stratified 30 according to group and gender.

Both venous and capillary blood samples were obtained at each time point. The capillary blood sample was taken from a finger prick immediately after the venous sample had been obtained by way of an 35 intravenous cannula. After-fasting samples of venous and capillary blood were obtained, the subject consumed GTT or TMB over a ten-minute period.

Additional blood samples were taken at 15, 30, 45, 60, 90 and 120 minutes after the start of the test meal (t_0 = start of test meal consumption).

Reproducibility of the repeated tests in 5 each group of subjects is expressed as the coefficient of variance which is calculated from the 4 repeated tests done by each subject. Reproducibility is determined for the 60-minute and 120-minute time points and for the incremental area under the curve.

10 The differences between plasma glucose and insulin responses of the different test meals (GTT and TMB) are determined primarily using the area under the curve and secondarily using each time point with analysis of variance of the repeated measurements.

15 Within-subject variability of blood glucose and insulin responses following ingestion of 75 grams glucose are compared with the reproducibility after ingestion of 50 grams of available carbohydrate in test bar format. In addition, the relationship 20 between the plasma glucose and insulin responses after oral glucose and the test bar meal are compared in nonobese and obese normal subjects, subjects with impaired glucose tolerance and subjects with type 2 diabetes treated by diet alone.

25 To date 44 GTT tests and 41 TMB tests have been completed. Six subjects have completed the study, and 16 subjects (8 normal, 5 IGT, and 3 diabetic) have taken at least 1 glucose and one bar test. The mean 2-hour postprandial plasma glucose of 30 these 16 subjects after the GTT varied from 3.6 mmol/L to 19.9 mmol/L. The mean 2-hour postprandial glucose after oral glucose was linearly related to the 2-hour postprandial glucose after the test bar ($r = 0.95$; $r^2 = 0.90$; $p < 0.001$). The data show that a 2-hour 35 postprandial plasma glucose of ≥ 8.7 mmol/L after the TMB corresponds to a 2-hour postprandial plasma glucose of ≥ 11.1 mmol/L after GTT (i.e., diabetes),

and that a 2-hour postprandial plasma glucose of \leq 6.3 mmol/L after the TMB corresponds to \leq 7.7 mmol/L after GTT (i.e., normal). These results suggest that the test bar will be useful as a valid screening test for 5 diabetes.

EXAMPLE 6

Effect of Acarbose on the Postprandial Blood Glucose Response to Ensure® and the Solid Test Meal

10 Ensure®, a liquid formula diet, has been used as a standard test meal in many clinical trials of acarbose in the treatment of diabetes. However, the type of carbohydrate in Ensure® differs markedly from that of a normal diet; starch contributes 25-30% 15 of energy in a normal diet, but Ensure® contains no starch. Thus, the pattern of postprandial blood glucose response after Ensure® may differ from that of a normal diet. In addition, acarbose may have a different effect on postprandial blood glucose after 20 consumption of Ensure® than after starchy foods. In order to compare the postprandial blood glucose response, and the effect of acarbose thereon, to white bread described in Example 2, Ensure® and the 98.0-gram solid test meal in the form of a bar ("TMB") as 25 described in Table I, we studied 2 groups of normal subjects on separate mornings after an overnight fast. On each day, subjects ate a test meal containing 50 grams of carbohydrate (total carbohydrate minus total dietary fiber). After-fasting finger-prick blood 30 samples for glucose analysis were obtained. Additional blood samples were taken at 15, 30, 45, 60, 90 and 120 minutes after the start of the test meal (t_0 = start of test meal consumption).

35 In one study, 9 subjects (5 female, 4 male, age 31 ± 2 years, BMI $22.9 \pm 1.4 \text{ kg/m}^2$) tested white bread, TMB or Ensure®. Compared to white bread, postprandial blood glucose after Ensure® tended to be

higher at 15 minutes ($p = 0.07$) and was significantly lower at 45 ($p = 0.003$), 60 ($p = 0.012$), 90 ($p = 0.025$) and 120 ($p = 0.007$) minutes. The incremental area under the curve (AUC) after Ensure®, 83 ± 12 5 mmol-min/L was $68 \pm 8\%$ that of white bread, 125 ± 15 mmol-min/L ($p = 0.07$). Blood glucose after the TMB was not significantly different from that after white bread at any time point, and the AUC after TMB, 110 ± 16 mmol-min/L, was similar to that after white bread. 10 The mean AUC after Ensure® was 75% that after the TMB.

In another study, 6 subjects (2 female, 4 male, age 34 ± 4 y, BMI 23.9 ± 1.4 kg/m²) tested Ensure® or TMB with 50 mg acarbose or placebo using a 15 randomized latin square design. The results of this study are shown in FIGS. 1, 2, and 3. The mean AUC after Ensure® plus placebo, 88 ± 11 mmol-min/L, was 73% of that after the TMB, 120 ± 16 mmol-min/L. The AUC after Ensure® plus acarbose, 56 ± 18 mmol-min/L, 20 tended to be less than after Ensure® plus placebo, but the difference was not significant. The AUC after TMB plus acarbose, 78 ± 8 mmol-min/L, was significantly less than after TMB plus placebo. Acarbose reduced the AUC after Ensure® by $35 \pm 20\%$ (not significant), 25 and after TMB by $30 \pm 11\%$ ($p < 0.05$). It is concluded the blood glucose response of the TMB is more representative of a normal diet than Ensure®. In normal subjects, acarbose reduces postprandial blood glucose to a similar extent after Ensure® and the TMB, 30 but the effect may be more consistent after the TMB.

WE CLAIM:

1. A solid oral diagnostic test meal comprising a carbohydrate source that provides a
5 medically controlled quantity of available carbohydrate when the meal is ingested by a vertebrate subject.
2. The solid diagnostic test meal of claim
10 1, wherein the carbohydrate source is a cereal grain selected from the group consisting of barley, oat, wheat, rye, corn, maize, sorghum and millet.
3. The solid diagnostic test meal of claim
15 3, wherein the cereal grain is oat.
4. The solid diagnostic test meal of claim
1 further comprising sources of dietary fat, dietary protein and, optionally, dietary fiber and flavoring.
20
5. The solid diagnostic test meal of claim
4, wherein the available carbohydrate is present in an amount in the range of about 50% to about 65% of the energy provided in the meal.
25
6. The solid diagnostic test meal of claim
4, wherein the dietary fat is present in an amount in the range of about 15% to about 30% of the energy provided in the meal.
30
7. The solid diagnostic test meal of claim
4, wherein the dietary protein is present in an amount in the range of about 10% to about 25% of the energy provided in the meal.
35

8. The solid diagnostic test meal of claim 1, wherein the test meal is provided in the form of a bar.

5 9. A solid diagnostic test bar comprising:

(a) a carbohydrate source that provides a medically controlled quantity of available carbohydrate in an amount in the range of about 50% to about 65% of the energy provided in the meal, wherein
10 the carbohydrate source is oat grain;

(b) a source of dietary fat, wherein the dietary fat is present in an amount in the range of about 15% to about 30% of the energy provided in the meal;

15 (c) a source of dietary protein, wherein the dietary protein is present in an amount in the range of about 10% to about 25% of the energy provided in the meal; and, optionally,

(d) a source of dietary fiber.

20

10. A nutritionally balanced meal comprising a carbohydrate source that provides a medically controlled quantity of available carbohydrate when the meal is ingested by a vertebrate
25 subject.

11. The nutritionally balanced meal of claim 10, wherein the carbohydrate source is a cereal grain selected from the group consisting of barley, oat, wheat, rye, corn, maize, sorghum and millet.
30

12. The nutritionally balanced meal of claim 11, wherein the cereal grain is oat.

35 13. The nutritionally balanced meal of claim 10 further comprising sources of dietary fat,

dietary protein and, optionally, dietary fiber and flavoring.

14. The nutritionally balanced meal of
5 claim 13, wherein the available carbohydrate is present in an amount in the range of about 50% to about 65% of the energy provided in the meal.

15. The nutritionally balanced meal of
10 claim 13, wherein the dietary fat is present in an amount in the range of about 15% to about 30% of the energy provided in the meal.

16. The nutritionally balanced meal of
15 claim 13, wherein the dietary protein is present in an amount in the range of about 10% to about 25% of the energy provided in the meal.

17. The nutritionally balanced meal of
20 claim 10, wherein the test meal is provided in the form of a bar.

18. A nutritionally balanced meal comprising:

25 (a) a carbohydrate source that provides a medically controlled quantity of available carbohydrate in an amount in the range of about 50% to about 65% of the energy provided in the meal, wherein the carbohydrate source is oat grain;

30 (b) a source of dietary fat, wherein the dietary fat is present in an amount in the range of about 15% to about 30% of the energy provided in the meal;

35 (c) a source of dietary protein, wherein the dietary protein is present in an amount in the range of about 10% to about 25% of the energy provided in the meal; and, optionally,

(d) a source of dietary fiber.

19. A method of diagnosing a disorder of carbohydrate metabolism in a vertebrate subject
5 comprising:

- (a) providing the solid oral diagnostic test meal of claim 1;
- (b) orally administering the test meal to the subject;
- 10 (c) assaying postprandial glucose concentration in a biological sample; and
- (d) comparing the postprandial glucose concentration in the biological sample with a reference glucose concentration.

15

20. The method of claim 19, wherein the biological sample is blood.

21. The method of claim 20, wherein the disorder of carbohydrate metabolism is selected from the group consisting of diabetes mellitus, impaired glucose tolerance, insulin resistance, non-insulin dependent diabetes, maturity onset diabetes, gestational diabetes and hyperinsulinemia.

25

22. The method of claim 21, wherein the carbohydrate source in the solid diagnostic test meal is a cereal grain selected from the group consisting of barley, oat, wheat, rye, corn, maize, 30 sorghum and millet.

23. The method of claim 22, wherein the cereal grain is oat.

35 24. The method of claim 21, wherein the solid diagnostic test meal further comprises sources

of dietary fat, dietary protein and, optionally, dietary fiber and flavoring.

25. The method of claim 24, wherein the
5 available carbohydrate in the solid diagnostic test meal is present in an amount in the range of about 50% to about 65% of the energy provided in the meal.

26. The method of claim 24, wherein the
10 dietary fat in the solid diagnostic test meal is present in an amount in the range of about 15% to about 30% of the energy provided in the meal.

27. The method of claim 24, wherein the
15 dietary protein in the solid diagnostic test meal is present in an amount in the range of about 10% to about 25% of the energy provided in the meal.

28. The method of claim 24, wherein the
20 solid diagnostic test meal is provided in the form of a bar.

29. The method of claim 20, wherein the solid diagnostic test meal comprises:

25 (a) a carbohydrate source that provides a medically controlled quantity of available carbohydrate in an amount in the range of about 50% to about 65% of the energy provided in the meal, wherein the carbohydrate source is oat grain;

30 (b) a source of dietary fat, wherein the dietary fat is present in an amount in the range of about 15% to about 30% of the energy provided in the meal;

35 (c) a source of dietary protein, wherein the dietary protein is present in an amount in the range of about 10% to about 25% of the energy provided in the meal; and, optionally,

(d) a source of dietary fiber.

30. A method of managing the dosage of a drug that decreases postprandial glucose concentration 5 in a biological sample from a vertebrate subject comprising:

- (a) providing the solid oral diagnostic test meal of claim 1;
- (b) orally administering the test meal 10 to the subject;
- (c) assaying postprandial glucose concentration in the biological sample; and
- (d) repeating steps (a) through (c) after administration of the drug.

15

31. The method of claim 30, wherein the biological sample is blood.

32. The method of claim 31, wherein the 20 carbohydrate source in the solid diagnostic test meal is a cereal grain selected from the group consisting of barley, oat, wheat, rye, corn, maize, sorghum and millet.

25

33. The method of claim 32, wherein the cereal grain is oat.

34. The method of claim 31, wherein the 30 solid diagnostic test meal further comprises sources of dietary fat, dietary protein and, optionally, dietary fiber and flavoring.

35. The method of claim 34, wherein the 35 available carbohydrate in the solid diagnostic test meal is present in an amount in the range of about 50% to about 65% of the energy provided in the meal.

36. The method of claim 34, wherein the dietary fat in the solid diagnostic test meal is present in an amount in the range of about 15% to about 30% of the energy provided in the meal.

5

37. The method of claim 34, wherein the dietary protein in the solid diagnostic test meal is present in an amount in the range of about 10% to about 25% of the energy provided in the meal.

10

38. The method of claim 34, wherein the solid diagnostic test meal is provided in the form of a bar.

15

39. The method of claim 31, wherein the solid diagnostic test meal comprises:

20

(a) a carbohydrate source that provides a medically controlled quantity of available carbohydrate in an amount in the range of about 50% to about 65% of the energy provided in the meal, wherein the carbohydrate source is oat grain;

25

(b) a source of dietary fat, wherein the dietary fat is present in an amount in the range of about 15% to about 30% of the energy provided in the meal;

30

(c) a source of dietary protein, wherein the dietary protein is present in an amount in the range of about 10% to about 25% of the energy provided in the meal; and, optionally,

(d) a source of dietary fiber.

35

40. A method of determining a postprandial glucose concentration in a biological sample from a vertebrate subject comprising:

(a) providing the solid oral diagnostic test meal of claim 1;

(b) orally administering the test meal to the subject; and

(c) assaying postprandial glucose concentration in a biological sample.

5

41. The method of claim 40, wherein the biological sample is blood.

10 42. The method of claim 41, wherein the carbohydrate source in the solid diagnostic test meal is a cereal grain selected from the group consisting of barley, oat, wheat, rye, corn, maize, sorghum and millet.

15 43. The method of claim 42, wherein the cereal grain is oat.

20 44. The method of claim 41, wherein the solid diagnostic test meal further comprises sources of dietary fat, dietary protein and, optionally, dietary fiber and flavoring.

25 45. The method of claim 44, wherein the available carbohydrate in the solid diagnostic test meal is present in an amount in the range of about 50% to about 65% of the energy provided in the meal.

30 46. The method of claim 44, wherein the dietary fat in the solid diagnostic test meal is present in an amount in the range of about 15% to about 30% of the energy provided in the meal.

35 47. The method of claim 44, wherein the dietary protein in the solid diagnostic test meal is present in an amount in the range of about 10% to about 25% of the energy provided in the meal.

48. The method of claim 44, wherein the solid diagnostic test meal is provided in the form of a bar.

5 49. The method of claim 41, wherein the solid diagnostic test meal comprises:

10 (a) a carbohydrate source that provides a medically controlled quantity of available carbohydrate in an amount in the range of about 50% to about 65% of the energy provided in the meal, wherein the carbohydrate source is oat grain;

15 (b) a source of dietary fat, wherein the dietary fat is present in an amount in the range of about 15% to about 30% of the energy provided in the meal;

(c) a source of dietary protein, wherein the dietary protein is present in an amount in the range of about 10% to about 25% of the energy provided in the meal; and, optionally,

20 (d) a source of dietary fiber.

50. A method of determining a postprandial insulin response in a vertebrate subject comprising:

25 (a) providing the solid oral diagnostic test meal of claim 1;

(b) orally administering the test meal to the subject; and

(c) assaying postprandial insulin concentration in a biological sample.

30

51. The method of claim 50, wherein the biological sample is blood.

35 52. The method of claim 51, wherein the carbohydrate source in the solid diagnostic test meal is a cereal grain selected from the group

consisting of barley, oat, wheat, rye, corn, maize, sorghum and millet.

53. The method of claim 52, wherein the
5 cereal grain is oat.

54. The method of claim 51, wherein the solid diagnostic test meal further comprises sources of dietary fat, dietary protein and, optionally,
10 dietary fiber and flavoring.

55. The method of claim 54, wherein the available carbohydrate in the solid diagnostic test meal is present in an amount in the range of about 50%
15 to about 65% of the energy provided in the meal.

56. The method of claim 54, wherein the dietary fat in the solid diagnostic test meal is present in an amount in the range of about 15% to
20 about 30% of the energy provided in the meal.

57. The method of claim 54, wherein the dietary protein in the solid diagnostic test meal is present in an amount in the range of about 10% to
25 about 25% of the energy provided in the meal.

58. The method of claim 54, wherein the solid diagnostic test meal is provided in the form of a bar.
30

59. The method of claim 51, wherein the solid diagnostic test meal comprises:

(a) a carbohydrate source that provides a medically controlled quantity of available
35 carbohydrate in an amount in the range of about 50% to about 65% of the energy provided in the meal, wherein the carbohydrate source is oat grain;

(b) a source of dietary fat, wherein the dietary fat is present in an amount in the range of about 15% to about 30% of the energy provided in the meal;

5 (c) a source of dietary protein, wherein the dietary protein is present in an amount in the range of about 10% to about 25% of the energy provided in the meal; and, optionally,

(d) a source of dietary fiber.

10

60. A method of diabetes self-diagnosis and self-monitoring in a vertebrate subject comprising:

(a) providing the solid oral diagnostic test meal of claim 1;

15 (b) orally administering the test meal to the subject; and

(c) assaying postprandial glucose levels in a biological sample.

20

61. The method of claim 60, wherein the biological sample is blood.

25

62. The method of claim 61, wherein the carbohydrate source in the solid diagnostic test meal is a cereal grain selected from the group consisting of barley, oat, wheat, rye, corn, maize, sorghum and millet.

30

63. The method of claim 62, wherein the cereal grain is oat.

35

64. The method of claim 61, wherein the solid diagnostic test meal further comprises sources of dietary fat, dietary protein and, optionally, dietary fiber and flavoring.

65. The method of claim 64, wherein the available carbohydrate in the solid diagnostic test meal is present in an amount in the range of about 50% to about 65% of the energy provided in the meal.

5

66. The method of claim 64, wherein the dietary fat in the solid diagnostic test meal is present in an amount in the range of about 15% to about 30% of the energy provided in the meal.

10

67. The method of claim 64, wherein the dietary protein in the solid diagnostic test meal is present in an amount in the range of about 10% to about 25% of the energy provided in the meal.

15

68. The method of claim 64, wherein the solid diagnostic test meal is provided in the form of a bar.

20

69. The method of claim 61, wherein the solid diagnostic test meal comprises:

25

(a) a carbohydrate source that provides a medically controlled quantity of available carbohydrate in an amount in the range of about 50% to about 65% of the energy provided in the meal, wherein the carbohydrate source is oat grain;

30

(b) a source of dietary fat, wherein the dietary fat is present in an amount in the range of about 15% to about 30% of the energy provided in the meal;

35

(c) a source of dietary protein, wherein the dietary protein is present in an amount in the range of about 10% to about 25% of the energy provided in the meal; and, optionally,

(d) a source of dietary fiber.

70. A kit for diagnosing disorders of carbohydrate metabolism in a vertebrate subject comprising a solid oral diagnostic test meal comprising a carbohydrate source that provides a 5 medically controlled quantity of available carbohydrate when the meal is ingested by the vertebrate subject.

71. A kit for managing the dosage of a drug 10 that decreases postprandial glucose concentration in a biological sample from a vertebrate subject comprising a solid oral diagnostic test meal comprising a carbohydrate source that provides a medically controlled quantity of available carbohydrate when the 15 meal is ingested by the vertebrate subject.

72. A kit for determining postprandial glucose concentration in a biological sample from a vertebrate subject comprising a solid oral diagnostic 20 test meal comprising a carbohydrate source that provides a medically controlled quantity of available carbohydrate when the meal is ingested by the vertebrate subject.

73. A kit for determining a postprandial 25 insulin response in a vertebrate subject comprising a solid oral diagnostic test meal comprising a carbohydrate source that provides a medically controlled quantity of available carbohydrate when the 30 meal is ingested by the vertebrate subject.

74. A kit for diabetes self-diagnosis and self-monitoring in a vertebrate subject comprising a solid oral diagnostic test meal comprising a 35 carbohydrate source that provides a medically controlled quantity of available carbohydrate when the meal is ingested by the vertebrate subject.

1/3




FIG. 1

2/3





FIG. 2

3/3





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 49/00, A23L 1/164		A3	(11) International Publication Number: WO 97/02050 (43) International Publication Date: 23 January 1997 (23.01.97)
(21) International Application Number: PCT/CA96/00434 (22) International Filing Date: 28 June 1996 (28.06.96) (30) Priority Data: 08/497,508 30 June 1995 (30.06.95) US 08/670,709 26 June 1996 (26.06.96) US		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant: VEXCO HEALTHCARE INC. [CA/CA]; Bow Valley Square 1, 630 202 6th Avenue S.W., Calgary, Alberta T2P 2R9 (CA). (72) Inventors: PALMASON, Carol; 435 49 Avenue S.W., Calgary, Alberta T2S 1G3 (CA). WOLEVER, Thomas, M., S.; 135 Mavety Street, Toronto, Ontario M6P 2L8 (CA). (74) Agents: ERRATT, Judy, A. et al.; Gowling, Strathy & Henderson, Suite 2600, 160 Elgin Street, Ottawa, Ontario K1P 1C3 (CA).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
		(88) Date of publication of the international search report: 17 April 1997 (17.04.97)	

(54) Title: SOLID ORAL DIAGNOSTIC TEST MEAL AND METHODS OF USE THEREOF

(57) Abstract

A solid oral diagnostic test meal is provided that contains a carbohydrate source that provides a medically controlled quantity of available carbohydrate when the meal is ingested by a vertebrate subject. In addition, methods and kits are provided for using the diagnostic test meal to monitor postprandial glucose and insulin levels, to diagnose disorders of carbohydrate metabolism, to manage subjects being treated with antidiabetic agents and to self-diagnose diabetes and self-manage diet and antidiabetic drug dosage.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International Application No

PC1/CA 96/00434

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K49/00 A23L1/164

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>NUTR. RES. (N. Y.) (1996), 16(6), 899-905 CODEN: NTRSDC; ISSN: 0271-5317, 1996, XP002025712</p> <p>WOLEVER, THOMAS M. S. ET AL: "Less variation of postprandial blood glucose after starchy test meals than oral glucose" see figures; tables ---</p>	1-74
X	<p>DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, vol. 112, no. 51, 1987, pages 1977-1983, XP002025713</p> <p>W. SICHERT-OEVERMANN : "BLUTGLUCOSE- UND INSULINVERLAUF BEI GESUNDEN UND DIABETIKERN NACH GABE ROHER VOLLKORNZUBEREITUNGEN, INSBESONDRE FRISCHKORNMÜSLI." see page 1977; table 3 ---</p>	1-29, 40-74



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

2

Date of the actual completion of the international search

25 February 1997

Date of mailing of the international search report

17. 03. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+ 31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 96/00434

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	US 5 472 952 A (SMIDT CARSTEN R ET AL) 5 December 1995 see claims ----	9-29
A	CARBOHYDRATE POLYMERS, vol. 21, 1993, BARKING GB, pages 189-194, XP002025714 C. DUBOIS: "CEREAL DIETARY FIBERS AFFECT POST-PRANDIAL LIPOPROTEINS IN HEALTHY HUMAN SUBJECTS" see page 190, column 1; figure 1 ----	10-18
P,X	CHEMICAL ABSTRACTS, vol. 125, no. 15, 7 October 1996 Columbus, Ohio, US; abstract no. 194285, FAIRCHILD, R. M. ET AL: "A new breakfast cereal containing guar gum reduces postprandial plasma glucose and insulin concentrations in normal-weight human subjects" XP002025718 see abstract & BR. J. NUTR. (1996), 76(1), 63-73 CODEN: BJNUAV;ISSN: 0007-1145, 1996, ----	1-29, 40-51, 54-69
P,X	CHEMICAL ABSTRACTS, vol. 125, no. 13, 23 September 1996 Columbus, Ohio, US; abstract no. 166493, GUEVIN, NATHALIE ET AL: "Postprandial glucose, insulin, and lipid responses to four meals containing unpurified dietary fiber in non- insulin -dependent diabetes mellitus (NIDDM), hypertriglyceridemic subjects" XP002025719 see abstract & J. AM. COLL. NUTR. (1996), 15(4), 389-396 CODEN: JONUDL;ISSN: 0731-5724, 1996, ----	19-29
X	CHEMICAL ABSTRACTS, vol. 98, no. 3, 17 January 1983 Columbus, Ohio, US; abstract no. 11290, FOELSCH, U. R. ET AL: "Effect of acarbose and fiber on glucose and hormone response to sucrose load or mixed meal" XP002025720 see abstract & INT. CONGR. SER. - EXCERPTA MED. (1982), 594, 97-106 CODEN: EXMDA4;ISSN: 0531-5131, 1982, ----	30-39
2		-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 96/00434

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BR. J. NUTRITION, vol. 71, 1994, pages 675-685, XP002025715</p> <p>C. CHERBUT: "INVOLVEMENT OF SMALL INTESTINAL MOTILITY IN BLOOD GLUCOSE RESPONSE TO DIETARY FIBRE IN MAN." see table 3</p> <p>---</p>	1-29, 40-74
X	<p>EUR. J. CLIN. NUTRITION, vol. 42, 1988, pages 519-526, XP002025716</p> <p>B. KARLSTRÖM: "EFFECTS OF FOUR MEALS WITH DIFFERENT KINDS OF DIETARY FIBRE ON GLUCOSE METABOLISM IN HEALTHY SUBJECTS AND NON-INSULIN-DEPENDENT DIABETIC PATIENTS." see table 3</p> <p>-----</p>	1-29, 40-74

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 96/00434

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 19-29, 60-69 because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 19-29, 60-69 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple invenions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PL1/CA 96/00434

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5472952 A	05-12-95	NONE	

THIS PAGE BLANK (USPTO)